Tarsus Pharmaceuticals (TARS) Net Margin (2021 - 2026)

Tarsus Pharmaceuticals' Net Margin history runs 6 years deep, the most recent figure standing at 4.25% for Q1 2026.

• In Q1 2026, Net Margin rose 2772.0% year-over-year to 4.25%; the TTM figure through Mar 2026 stood at 8.6% (up 3544.0% YoY), while the FY2025 annual figure was 14.72%, up 4845.0% from the prior year.
• Net Margin was 4.25% for Q1 2026 at Tarsus Pharmaceuticals, down from 4.11% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 4.11% in Q4 2025 to a low of 3680.52% in Q1 2022.
• Historically, Net Margin has averaged 503.51% across 5 years, with a median of 48.81% in 2024.
• Biggest YoY gain for Net Margin was 415072 bps in 2022; the steepest drop was 371166 bps in 2022.
• A 5-year view of Net Margin shows it stood at 136.26% in 2022, then tumbled by 138 bps to 324.72% in 2023, then jumped by 89 bps to 34.76% in 2024, then soared by 88 bps to 4.11% in 2025, then slipped by 3 bps to 4.25% in 2026.
• The last three Net Margin figures came in at 4.25% (Q1 2026), 4.11% (Q4 2025), and 10.69% (Q3 2025), per Business Quant data.